All In Biotech

Drug Trial Radar · NCT06169579

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

A Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

96

Planned (sponsor's estimate)

Start

Feb 4, 2024

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
Collaborators
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.; Sun Yat-Sen University Cancer Center
First posted
Dec 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.

Conditions

  • Advanced Solid Tumor

Interventions

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally over continuous 28-days cycles.

  • ND-003 tabletsDrug

    ND-003 tablets will be administered orally over continuous 28-days cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT)Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)
  2. Maximum tolerated dose (MTD)Time frame: 4 days after single oral administration and the first cycle of multiple administration (28 days)
  3. Adverse Events (AE) assessed by CTCAE ver5.0.Time frame: through study completion, an average of 1 year

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • the first hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Sun Yat-sen University cancer center

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, Guangdong, China

  • Zhanjiang Central Hospital, Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • the Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Tongji Hospital Tongji Medical College of HUST

    Wu’an, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Shandong Cancer Hospital & Institute

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • The Second People's Hospital of Neijiang

    Neijiang, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.